As to molecular tumor features, the significant survival advantage associated with a high immune response score was maintained in patients with MSS but not in those with MSI colon cancer, and in those with wild-type RAS/BRAF but not in those with mutated colon cancers. This evidence concerns the gene BRAF and malignant colon neoplasm.